Lauren P. Carter

This paper describes the scalable production of a de novo SARS-CoV-2 antiviral miniprotein in E. coli, achieving high purity and yield for preclinical and clinical use.

The paper measures conformational fluctuations of protein domains using hydrogen-deuterium exchange mass spectrometry and uses computational modeling to design mutations that stabilize low-stability segments.

This paper describes a miniprotein inhibitor that neutralizes multiple SARS-CoV-2 variants and protects mice against them when administered post-exposure.

This paper describes a designed IL-21 mimic, 21h10, which shows potent antitumor activity in multiple models and reduces toxicity through TNF blockade.

This study develops a multivalent nanoparticle vaccine against EBOV and SUDV, showing protection in rodents from lethal infection.

This paper designs high-affinity proteins that bind to convex protein sites using geometrically matching concave scaffolds, achieving low nanomolar to picomolar affinities.

The paper designs closed repeat proteins with central pockets using deep learning and validates them in E. coli, showing structural consistency and potential for small molecule binding.

The paper designs EndoTags to trigger endocytosis and degradation of target proteins, enabling tissue-specific targeting and therapeutic applications.

The paper introduces a thermodynamically coupled biosensor to rapidly detect neutralizing antibodies against SARS-CoV-2 strains in serum samples.

The paper designs and characterizes trivalent miniprotein binders that neutralize SARS-CoV-2 variants with low pM IC50 values and provide prophylactic and therapeutic protection in mice.

This paper describes an engineered SARS-CoV-2 RBD variant that shows improved immunogenicity in mice and protective immunity in hamsters.

The paper predicts SARS-CoV-2 B-cell epitopes using computational methods and validates them with ELISA, finding two antigens with high sensitivity and specificity for serological diagnosis of COVID-19.

The paper designs picomolar SARS-CoV-2 miniprotein inhibitors using computational methods and experimental validation, showing high potency and structural similarity to computational models.